Mismatched Unrelated vs Matched Related Donor Transplant With Posttransplant Cyclophosphamide Among Patients - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparison of Unrelated Mismatched and Related Matched Donor Transplants with Posttransplant Cyclophosphamide in Patients

  • By

  • Rohtesh S. Mehta

  • Yosra M. Aljawai

  • Partow Kebriaei

  • Warren Fingrut

  • Portia Smallbone

  • Betul Oran

  • Amanda Olson

  • Uday Popat

  • Richard E. Champlin

  • Elizabeth J. Shpall

  • July 20, 2026

Share

  • 1

    Relapse of malignant tumors is a major barrier to long-term survival after allogeneic hematopoietic cell transplant (HCT).

  • 2

    Emerging evidence suggests that matched unrelated donors (MUDs) may have a stronger graft-vs-leukemia effect than matched related donors (MRDs).

  • 3

    The study aimed to compare clinical outcomes between MRD and mismatched unrelated donor (MMUD) transplants in the posttransplant cyclophosphamide era.

  • 4

    Primary outcomes included disease-free survival (DFS) and overall survival (OS), analyzed using inverse probability of treatment weighting and Cox proportional hazards models.

  • 5

    The study adhered to ethical guidelines and used robust statistical methods to address confounding factors and ensure the reliability of the results.

Original Source(s)

Mismatched Unrelated vs Matched Related Donor Transplant With Posttransplant Cyclophosphamide Among Patients

  • by Rohtesh S. Mehta, Yosra M. Aljawai, Partow Kebriaei, Warren Fingrut, Portia Smallbone, Betul Oran, Amanda Olson, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall

  • July 20, 2026

Related Content

Moving Cancer Survivorship Into Routine Care—Why Are We Still Not Ready for Change?

Efficiency and Sustainability in the Skin Cancer Excision Pathway: Life Cycle Assessment and Process Map

Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer

An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.

  • by

  • August 14, 2026

  • 6 min